Exonics Therapeutics

One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States

About Exonics Therapeutics

At Exonics Therapeutics, our mission is to permanently correct genetic mutations resulting in neuromuscular diseases like Duchenne muscular dystrophy. Duchenne is a devastating muscle disease in children, primarily boys, caused by the absence of dystrophin. Our approach utilizes gene editing technologies such as CRISPR/Cas9 to correct a majority of the genetic mutations in Duchenne, and enable dystrophin production.

YEAR FOUNDED:
2017

LEADERSHIP:
CEO – John Ripple

8 articles about Exonics Therapeutics

Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

7/10/2019

As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics

6/7/2019

Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

6/6/2019

Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1 by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs

8/31/2018

Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
Little Exonics Adds Merck's Larger-Than-Life R&D Chief to Its Board of Directors

1/30/2018

Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.
After $40M Financing, Exonics Therapeutics to Start Hiring for Cambridge Lab

11/9/2017

The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD.
Cambridge's Exonics Therapeutics Scores $40M

11/8/2017

Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group.
CRISPR/Cas9 Startup Exonics Therapeutics Launches in Boston

2/28/2017